Everything below concerns GLP-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
Cocaine dependence develops after even brief periods of regular cocaine use. About 25% of adults with attention deficit hyperactivity disorder (ADHD) use cocaine, and 10% develop a cocaine use disorder during their lifetime. Because cocaine use can worsen health outcomes, adults with ADHD should be screened for cocaine use disorder and referred for treatment if needed. Cocaine-dependent patients with high neuroticism scores are more likely to experience cocaine-induced psychotic symptoms, regardless of other drug use factors, making personality assessment important for risk identification and patient warning. Cocaine withdrawal symptoms group into two types: depressive (e.g., depression, craving, insomnia) and somatic (e.g., increased appetite, fatigue). Depressive symptoms are linked to worse outcomes like longer depression, treatment, and risky behaviors.
The study of chemical kinetics is used to determine the rate law for a reaction. The rate law provides a quantitative relationship between the rate of a chemical reaction and the concentrations or pressures of the chemical species present. Rate laws must be determined by experimental measurement and generally cannot be elucidated from the chemical equation. The experimentally determined rate law refers to the stoichiometry of the transition state structure relative to the ground state structure. Determination of the rate law was historically accomplished by monitoring the concentration of a reactant during a reaction through gravimetric analysis, but today it is almost exclusively done through fast and unambiguous spectroscopic techniques. In most cases, the determination of rate equations is simplified by adding a large excess ("flooding") all but one of the reactants.
=== Pharmacokinetics === Methylliberine has a short half-life of only 1.5 hours compared to the 5- to 7-hour half-life of caffeine. An interaction study showed concomitant administration of both caffeine and methylliberine increases the half-life of caffeine by about 2 fold. This is likely due to inhibition of the CYP1A2 enzyme.
== Publications == Eke has authored or co-authored over 200 peer-reviewed publications in leading journals, including The New England Journal of Medicine, Journal of the American Medical Association (JAMA), The Lancet, Clinical Infectious Diseases (CID), Clinical Pharmacology and Therapeutics, CPT Pharmacometrics and Systems Pharmacology, and the British Journal of Obstetrics and Gynecology. His published work has garnered over 7,800 citations, and spans topics such as perinatal pharmacology, maternal co-morbidities, and global health. In addition to original research, he has contributed expert commentaries and reviews, particularly in the fields of pharmacologic safety in pregnancy and maternal HIV care. His work is frequently cited in policy documents by organizations such as the American College of Obstetricians and Gynecologists (ACOG), the National Institute of Child Health and Human Development (NICHD), and the U.S. Food and Drug Administration (FDA).
Sources: en.wikipedia.org
The second phase uses a modified MaxSub algorithm: a single 7 reside aligned pair in each proteins is used to orient the two full length protein structures to maximally superimpose these just these 7 C-alpha, then in this orientation it scans for any additional aligned pairs that are close in 3D. It re-orients the structures to superimpose this expanded set and iterates until no more pairs coincide in 3D. This process is restarted for every 7 residue window in the seed alignment. The output is the maximal number of atoms found from any of these initial seeds. This statistic is converted to a calibrated E-value for the similarity of the proteins. Mammoth makes no attempt to re-iterate the initial alignment or extend the high quality sub-subset. Therefore, the seed alignment it displays can't be fairly compared to DALI or TM align as it was formed simply as a heuristic to prune the search space. (It can be used if one wants an alignment based solely on local structure-motif similarity agnostic of long range rigid body atomic alignment.) Because of that same parsimony, it is well over ten times faster than DALI, CE and TM-align. It is often used in conjunction with these slower tools to pre-screen large data bases to extract the just the best E-value related structures for more exhaustive superposition or expensive calculations.
== See also == Capillary electrophoresis–mass spectrometry Ion-mobility spectrometry–mass spectrometry Liquid chromatography–mass spectrometry Prolate trochoidal mass spectrometer Pyrolysis–gas chromatography–mass spectrometry
This process is extremely painful and can traumatize the animal. Freeze branding gained popularity in the middle of the 20th century as a less painful way to permanently mark and identify animals. There has been debate as to whether freeze branding is truly less painful than hot branding, but scientific studies conducted to compare the relative pain of the two methods have concluded that freeze branding is indeed less distressing to the animal being marked. Freeze brands are made for a variety of purposes. For example, they are used to indicate that an animal belongs to a particular herd, all members of which are marked with the same brand. They are also used to indicate via a unique pattern that an individual animal is a particular person's or ranch's property. Freeze branding is also used to tag wild animals that will be recaptured for later research.
== Works == Newsom, Gavin; Dickey, Lisa (February 7, 2013). Citizenville: How to Take the Town Square Digital and Reinvent Government. Penguin. ISBN 978-1101605813. Newsom, Gavin (February 24, 2026). Young Man in a Hurry: A Memoir of Discovery. Penguin. ISBN 978-1984881939.
== Clinical significance == Activation of the ERK1/2 pathway by aberrant RAS/RAF signalling, DNA damage, and oxidative stress leads to cellular senescence. Low doses of DNA damage resulting from cancer therapy cause ERK1/2 to induce senescence, whereas higher doses of DNA damage fail to activate ERK1/2, and thus induce cell death by apoptosis.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.